+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome



Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome



Journal of Hepatology 44(2): 400-406



Whether primary biliary cirrhosis (PBC)-autoimmune hepatitis (AIH) overlap syndrome requires immunosuppressive therapy in addition to ursodeoxycholic acid (UDCA) is a controversial issue. Seventeen patients with simultaneous form of strictly defined overlap were followed for 7.5 years. First-line treatment was UDCA alone (UDCA) in 11 and combination of immunosuppressors and UDCA (UDCA + IS) in 6. Characteristics at presentation were not significantly different between the 2 groups. In the UDCA + IS group (f-up 7.3 years), biochemical response in terms of AIH features (ALT<2ULN and IgG < 16 g/L) was achieved in 4/6 and fibrosis did not progress. In the UDCA group, biochemical response was observed in three patients together with stable or decreased fibrosis (f-up 4.5 years) whereas the eight others were non-responders with increased fibrosis in four (f-up 1.6 years). Seven of these eight patients subsequently received combined therapy for 3 years. Biochemical response was obtained in 6/7 and no further increase of fibrosis was demonstrated. Overall, fibrosis progression in non-cirrhotic patients occurred more frequently under UDCA monotherapy (4/8) than under combined therapy (0/6) (P = 0.04). Combination of UDCA and immunosuppressors appears to be the best therapeutic option for strictly defined PBC-AIH overlap syndrome.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012271073

Download citation: RISBibTeXText

PMID: 16356577

DOI: 10.1016/j.jhep.2005.10.017


Related references

Primary biliary cirrhosis -autoimmune hepatitis overlap syndrome Long term outcome and response to therapy. Hepatology 36(4 Part 2): 500A, 2002

Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis. Hepato-Gastroenterology 57(99-100): 441-446, 2010

Overlap of primary biliary cirrhosis and autoimmune hepatitis: Characteristics, therapy, and long term outcomes. Journal of Gastroenterology and Hepatology 25(2): 376-382, 2010

Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28(2): 296-301, 1998

Biochemical, histological parameters and response to UDCA treatment in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Journal of Hepatology 34(Supplement 1): 216, 2001

Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Hepato-Gastroenterology 49(47): 1195-1200, 2002

Syndrome of overlap of autoimmune hepatitis and primary biliary cirrhosis with the outcome in cirrhosis of the liver, complicated by fatal bleeding in the small intestine. Eksperimental'naia i Klinicheskaia Gastroenterologiia 2013(2): 76-82, 2013

Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. American Journal of Gastroenterology 102(6): 1244-1250, 2007

Flare-up of autoimmune hepatitis after delivery in a patient with primary biliary cirrhosis: postpartum overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis. Digestive Diseases and Sciences 50(1): 201-206, 2005

The usefulness of IgG and IgM immunostaining of periportal inflammatory cells (plasma cells and lymphocytes) for the distinction of autoimmune hepatitis and primary biliary cirrhosis and their staining pattern in autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. American Journal of Clinical Pathology 133(3): 430-437, 2010

Outcome of pregnancy in patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome: a report of two cases. Clinics and Research in Hepatology and Gastroenterology 35(10): 687-689, 2012

Autoimmune hemolityc anemia concomitant with sequential autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Hashimoto's thyroiditis: a new entity of autoimmune polyendocrine syndrome. Journal of Endocrinological Investigation 32(3): 287-288, 2009

Living donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. 2012

Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome. Seminars in Liver Disease 28(1): 128-134, 2008

Analysis of Predictive Factors of Non Response to Therapy in Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndromes a Retrospective Singlecenter Experience. Journal of Hepatology 64(2): S641-S642, 2016